Hyperphosphataemia sensitizes renally impaired rats to the profibrotic effects of gadodiamide

British Journal of Pharmacology

Volumn 165, Issue 4 B, 2012, Pages 1151-1162

  Fretellier, N ^a,e   Idee J M ^a   Bruneval, P ^b   Guerret, S ^c   Daubine F ^d   Jestin, G ^a   Factor, C ^a   Poveda, N ^a   Dencausse, A ^a   Massicot, F ^e   Laprevote O ^e,f   Mandet, C ^b   Bouzian, N ^a   Port, M ^a   Corot, C ^a  

^a Laboratoire Guerbet   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c Novotec   (France)

^d Atlantic Bone Screen   (France)

^e FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

^f HÔPITAL LARIBOISIÈRE   (France)

Author keywords

contrast agents; gadolinium; gadolinium chelates; hyperphosphataemia; magnetic resonance imaging; nephrogenic systemic fibrosis; relaxometry; renal impairment

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOLINIUM CHELATE; GADOTERATE MEGLUMINE; LIGAND; PENTETIC ACID; PHOSPHATE; SODIUM CHLORIDE; TETRAXETAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISSOCIATION; DRUG BLOOD LEVEL; DRUG BONE LEVEL; DRUG EFFECT; DRUG RELEASE; DRUG SENSITIZATION; DRUG TISSUE LEVEL; HYPERPHOSPHATEMIA; KIDNEY DYSFUNCTION; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NEPHRECTOMY; NEPHROGENIC SYSTEMIC FIBROSIS; NONHUMAN; PHOSPHATE INTAKE; PRIORITY JOURNAL; RAT; RISK FACTOR; SKIN; SKIN DEFECT; WISTAR RAT;

ANIMALS; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; FEMUR; GADOLINIUM; GADOLINIUM DTPA; HYPERPHOSPHATEMIA; LIVER; MALE; NEPHROGENIC FIBROSING DERMOPATHY; PROCOLLAGEN-PROLINE DIOXYGENASE; RATS; RATS, WISTAR; RENAL INSUFFICIENCY; RISK FACTORS; SKIN; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84856340037     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01585.x     Document Type: Article

References (56)

1. Abraham JL, Thakral C, Skov L, Rossen K, Marckmann P, (2008). Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Br J Dermatol 158: 273-280.
2. Bhagavathula N, Dame MK, Dasilva M, Jenkins W, Aslam MN, Perone P, et al,. (2010). Fibroblast response to gadolinium: role for platelet-derived growth factor receptor. Invest Radiol 45: 769-777.
3. Braverman IM, Cowper SE, (2010). Nephrogenic systemic fibrosis. F1000 Med Rep 2: 84.
4. Broome DR, (2008). Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Eur J Radiol 66: 230-234.
5. Bucala R, (2008). Circulating fibrocytes: cellular basis for NSF. J Am Coll Radiol 5: 36-39.
6. Cohen PR, Rapini RP, Farhood AI, (1997). Dermatopathologic advances in clinical research. The expression of antibody to CD34 in mucocutaneous lesions. off. Dermatol Clin 15: 159-176. (Pubitemid 27034663)
7. Coladonato JA, (2005). Control of hyperphosphataemia among patients with ESRD. J Am Soc Nephrol 16 (Suppl. 2): 107-114.
8. Cowper SE, (2007). Nephrogenic systemic fibrosis: a review and exploration of the role of gadolinium. Adv Dermatol 23: 131-154.
9. Cowper SE, Su LD, Bhawan J, Robin HS, LeBoit PE, (2001). Nephrogenic fibrosing dermopathy. Am J Dermatopathol 23: 383-393. (Pubitemid 32938907)
10. Cowper SE, Rabach R, Girardi M, (2008). Clinical and histological findings in nephrogenic systemic fibrosis. Eur J Radiol 66: 191-199.
11. Crissman JW, Goodman DG, Hildebrandt PK, Maronpot RR, Prater DA, Riley JH, et al,. (2004). Best practices guideline: toxicologic histopathology. Toxicol Pathol 32: 126-131. (Pubitemid 38250001)
12. DaSilva M, Deming MO, Fligiel SE, Dame MK, Johnson KJ, Swartz RD, et al,. (2010). Responses of human skin in organ culture and human skin fibroblasts to a gadolinium-based MRI contrast agent: comparison of skin from patients with end-stage renal disease and skin from healthy subjects. Invest Radiol 45: 733-739.
13. Edward M, Quinn JA, Burden AD, Newton BB, Jardine AG, (2010). Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation. Radiology 256: 735-743.
14. Ersoy H, Rybicki FJ, (2007). Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis. J Magn Reson Imaging 26: 1190-1197. (Pubitemid 350058285)
15. Frenzel T, Lengsfeld P, Schirmer H, Hütter J, Weinmann HJ, (2008). Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37°C. Invest Radiol 73: 817-828.
16. Fretellier N, Idée JM, Guerret S, Hollenbeck C, Hartmann D, González W, et al,. (2011a). Clinical, biological, and skin histopathological effects of ionic macrocyclic and nonionic linear gadolinium chelates in a rat model of nephrogenic systemic fibrosis. Invest Radiol 46: 85-93.
17. Fretellier N, Idée JM, Dencausse A, Karroum O, Guerret S, Poveda N, et al,. (2011b). comparative in vivo dissociation of gadolinium chelates in renally impaired rats: a relaxometry study. Invest Radiol 46: 292-300.
18. George SJ, Webb SM, Abraham JL, Cramer SP, (2010). Synchrotron X-ray analyses demonstrate phosphate-bound gadolinium in skin in nephrogenic systemic fibrosis. Br J Dermatol 163: 1077-1081.
19. Gorres KL, Raines RT, (2010). Prolyl 4-hydroxylase. Crit Rev Biochem Mol Biol 45: 106-124.
20. Grant D, Johnsen H, Juelsrud A, Løvhaug D, (2009). Effects of gadolinium contrast agents in naïve and nephrectomised rats: relevance to nephrogenic systemic fibrosis. Acta Radiol 50: 156-169.
21. Grobner T, (2006). Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21: 1104-1108.
22. Haylor J, Dencausse A, Vickers M, Nutter F, Jestin G, Slater D, et al,. (2010). Nephrogenic gadolinium biodistribution and skin cellularity following a single injection of Omniscan in the rat. Invest Radiol 45: 507-512.
23. Idée JM, Port M, Robic C, Medina C, Sabatou M, Corot C, (2009). Role of thermodynamic and kinetic parameters in gadolinium chelate stability. J Magn Reson Imaging 30: 1249-1258.
24. Jiang Y, Wang M, (2008). Hyperphosphataemia-induced hyperparathyroidism in 5/6 nephrectomized rats: development of a new animal model. Chin Med J 121: 2440-2443.
25. Jiménez SA, Artlett CM, Sandorfi N, Derk C, Latinis K, Sawaya H, et al,. (2004). Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum 50: 2660-2666. (Pubitemid 39062729)
26. Kelly B, Petitt M, Sanchez R, (2008). Nephrogenic systemic fibrosis is associated with transforming growth factor beta and Smad without evidence of renin-angiotensin system involvement. J Am Acad Dermatol 58: 1025-1030. (Pubitemid 351657614)
27. Kelly BC, Markle LS, Vickers JL, Petitt MS, Raimer SS, McNeese C, (2010). The imbalanced expression of matrix metalloproteinases in nephrogenic systemic fibrosis. J Am Acad Dermatol 63: 483-489.
28. LeRoy EC, Trojanowska MI, Smith EA, (1990). Cytokines and human fibrosis. Eur Cytokine Netw 1: 215-219.
29. Li JX, Liu JC, Wang K, Yang XG, (2010). Gadolinium-containing bioparticles as active antity to promote cell cycle progression in mouse embryo fibroblast NIH3T3 cells. J Biol Inorg Chem 15: 547-557.
30. Lorusso V, Arbughi T, Tirone P, de Haën C, (1999). Pharmacokinetics and tissue distribution in animals of gadobenate ion, the magnetic resonance imaging contrast enhancing component of gadobenate dimeglumine 0.5 M solution for injection (MultiHance). J Comput Assist Tomogr 23 (Suppl. 1): 181-194.
31. Mahl A, Heining P, Ulrich P, Jakubowski J, Bobadilla M, Zeller W, et al,. (2000). Comparison of clinical pathology parameters with two different blood sampling techniques in rats: retrobulbar plexus versus sublingual vein. Lab Anim 34: 351-361.
32. Marckmann P, Skov L, Rossen K, Heaf JG, Thomsen HS, (2007). Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant 22: 3174-3178. (Pubitemid 350202540)
33. Matrisian LM, (1990). Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 6: 121-125.
34. Nickoloff BJ, (1991). The human progenitor cell antigen (CD34) is localized on endothelial cells, dermal dendritic cells, and perifollicular cells in formalin-fixed normal skin, and on proliferating endothelial cells and stromal spindle-shaped cells in Kaposi's sarcoma. Arch Dermatol 127: 523-529.
35. Oste L, Behets GJ, Dams G, Bervoets AR, Marynissen RL, Geryl H, et al,. (2007). Role of dietary phosphorus and degree of uremia in the development of renal bone disease in rats. Ren Fail 29: 1-12.
36. Peak A, Sheller A, (2007). Risk factors for developing gadolinium-induced nephrogenic systemic fibrosis. Ann Pharmacother 41: 1481-1485. (Pubitemid 47311368)
37. Perazella MA, Reilly RF, (2011). Imaging patients with kidney disease: how do we approach contrast-related toxicity? Am J Med Sci 341: 215-221.
38. Pietsch H, Lengsfeld P, Steger-Hartmann T, Löwe A, Frenzel T, Hütter J, et al,. (2009). Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents. Invest Radiol 44: 226-233.
39. Pietsch H, Raschke M, Ellinger-Ziegelbauer H, Jost G, Walter J, Frenzel T, et al,. (2011). The role of residual gadolinium in the induction of nephrogenic systemic fibrosis-like skin lesions in rats. Invest Radiol 46: 48-56.
40. Port M, Corot C, Violas X, Robert P, Raynal I, Gagneur G, (2005). How to compare the efficiency of albumin-bound and nonalbumin-bound contrast agents in vivo: the concept of dynamic relaxivity. Invest Radiol 40: 565-573. (Pubitemid 41208633)
41. Port M, Idée JM, Medina C, Robic C, Sabatou M, Corot C, (2008). Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. Biometals 21: 469-490.
42. Prince MR, Zhang H, Morris M, MacGregor JL, Grossman ME, Silberzweig J, et al,. (2008). Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology 248: 807-816.
43. Sanchez CP, He YZ, Leiferman E, Wilsman NJ, (2004). Bone elongation in rats with renal failure and mild or advanced secondary hyperparathyroidism. Kidney Int 65: 1740-1748. (Pubitemid 38591022)
44. Schieren G, Gambichler T, Skrygan M, Burkert B, Altmeyer P, Rump LC, et al,. (2010). Balance of profibrotic and antifibrotic [corrected] signaling in nephrogenic systemic fibrosis skin lesions. Am J Kidney Dis 55: 1040-1049.
45. Schiller M, Javelaud D, Mauviel A, (2004). TGF-beta-induced SMAD signaling and gene regulation: consequences for extracellular matrix remodeling and wound healing. J Dermatol Sci 35: 83-92. (Pubitemid 38969031)
46. Sieber MA, Pietsch H, Walter J, Haider W, Frenzel T, Weinmann HJ, (2008a). A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol 43: 65-75.
47. Sieber MA, Lengsfeld P, Frenzel T, Golfier S, Schmitt-Willich H, Siegmund F, et al,. (2008b). Preclinical investigation to compare different gadolinium-based contrast agents regarding the propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol 18: 2164-2173.
48. Spinazzi A, Lorusso V, Pirovano G, Kirchin M, (1999). Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. Acad Radiol 6: 282-291. (Pubitemid 32673373)
49. Steger-Hartmann T, Raschke M, Riefke B, Pietsch H, Sieber MA, Walter J, (2009). The involvement of pro-inflammatory cytokines in nephrogenic systemic fibrosis. A mechanistic hypothesis based on preclinical results from a rat model treated with gadodiamide. Exp Toxicol Pathol 61: 537-552.
50. Swartz RD, Crofford LJ, Phan SH, Ike RW, Su LD, (2003). Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med 114: 563-572. (Pubitemid 36577259)
51. Thakral C, Abraham JL, (2009). Gadolinium-induced nephrogenic systemic fibrosis is associated with insoluble Gd deposits in tissues: in vivo transmetallation confirmed by microanalysis. J Cutan Pathol 36: 1244-1254.
52. Thakral C, Alhariri J, Abraham JL, (2007). Long-term retention of gadolinium in tissues from nephrogenic systemic fibrosis patient after multiple gadolinium-enhanced MRI scans: case report and implications. Contrast Media Mol Imaging 2: 199-205. (Pubitemid 47542596)
53. US Food and Drugs Administration CfDEaR (2005). Guidance for industry. Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. (last accessed 29 March 2011).
54. Vakil V, Sung JJ, Piecychna M, Crawford JR, Kuo P, Abu Alfa AK, et al,. (2009). Gadolinium-containing magnetic resonance image contrast agents promotes fibrocytes differentiation. J Magn Reson Imaging 20: 1284-1288.
55. Varani J, DaSilva M, Warner RL, Deming MO, Barron AG, Johnson KJ, (2009). Effects of gadolinium-based magnetic resonance imaging contrast agents on human skin in organ culture and human skin fibroblasts. Invest Radiol 44: 74-81.
56. Wilford C, Fine JD, Boyd AS, Sanyal S, Abraham JL, Kantrow SM, (2010). Nephrogenic systemic fibrosis: report of an additional case with granulomatous inflammation. Am J Dermatopathol 32: 71-75.